GB8810934D0
(en)
*
|
1987-05-26 |
1988-06-15 |
Ici America Inc |
Amides
|
GB8810933D0
(en)
*
|
1987-05-26 |
1988-06-15 |
Ici America Inc |
Heterocyclic compounds
|
US5705585A
(en)
*
|
1993-06-30 |
1998-01-06 |
Arqule, Inc. |
Aminimide-containing molecules and materials as molecular recognition agents
|
US5670480A
(en)
*
|
1994-01-05 |
1997-09-23 |
Arqule, Inc. |
Method of making polymers having specific properties
|
US7034110B2
(en)
*
|
1994-01-05 |
2006-04-25 |
Arqule, Inc. |
Method of identifying chemical compounds having selected properties for a particular application
|
US5734082A
(en)
*
|
1994-10-20 |
1998-03-31 |
Arqule Inc. |
Hydroxyethyl aminimides
|
US5712171A
(en)
*
|
1995-01-20 |
1998-01-27 |
Arqule, Inc. |
Method of generating a plurality of chemical compounds in a spatially arranged array
|
WO1996031263A1
(fr)
*
|
1995-04-06 |
1996-10-10 |
Arqule, Inc. |
Procede de purification, d'analyse et de caracterisation rapides de collections de composes chimiques
|
US5962412A
(en)
*
|
1996-06-10 |
1999-10-05 |
Arqule, Inc. |
Method of making polymers having specific properties
|
BRPI0717767A2
(pt)
*
|
2006-10-19 |
2013-11-12 |
Signal Pharm Llc |
Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer, uma condição inflamatória, uma condição imunológica ou uma condição metabólica, e para inibir uma quinase em uma célula de expressa a dita quinase
|
US8110578B2
(en)
|
2008-10-27 |
2012-02-07 |
Signal Pharmaceuticals, Llc |
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
|
CN102686225A
(zh)
|
2009-10-26 |
2012-09-19 |
西格诺药品有限公司 |
杂芳基化合物的合成和纯化方法
|
EP3466423B1
(fr)
|
2011-10-19 |
2021-07-28 |
Signal Pharmaceuticals, LLC |
Traitement du cancer au moyen d'inhibiteurs de la kinase tor
|
EP2785325B1
(fr)
|
2011-12-02 |
2018-08-22 |
Signal Pharmaceuticals, LLC |
Compositions pharmaceutiques de 7-(6-(2-hydroxypropan-2-y1)pyridin-3-yl)-1-((trans)-4-méthoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, forme solide de celles-ci et leurs procédés d'utilisation
|
MX358303B
(es)
|
2012-02-24 |
2018-08-14 |
Signal Pharm Llc |
Uso de 7-(6-(2-hidroxipropan-2il) piridin-3-il)-1-((1r,4r)4-metoxi ciclohexil)-3, 4-dihidropirazin-[2,3-b] pirazin-2(1h)-ona o una sal, estereoisómero o tautómero aceptable farmaceuticamente del mismo, en combinación con una cantidad efectiva de erlotinib o azacitidina para preparar un composición farmacéutica en el tratamiento de cáncer de pulmón de cédula no pequeña, avanzado.
|
AU2013203714B2
(en)
|
2012-10-18 |
2015-12-03 |
Signal Pharmaceuticals, Llc |
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
|
PE20151995A1
(es)
|
2013-01-16 |
2016-01-13 |
Signal Pharm Llc |
Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos
|
US9358232B2
(en)
|
2013-04-17 |
2016-06-07 |
Signal Pharmaceuticals, Llc |
Methods for treating cancer using TOR kinase inhibitor combination therapy
|
CN105377299B
(zh)
|
2013-04-17 |
2018-06-12 |
西格诺药品有限公司 |
用于治疗前列腺癌的包含二氢吡嗪并-吡嗪化合物和雄激素受体拮抗剂的组合疗法
|
WO2014172426A1
(fr)
|
2013-04-17 |
2014-10-23 |
Signal Pharmaceuticals, Llc |
Traitement du cancer par des dihydropyrazino-pyrazines
|
NZ629332A
(en)
|
2013-04-17 |
2017-05-26 |
Signal Pharm Llc |
Treatment of cancer with dihydropyrazino-pyrazines
|
JP6382949B2
(ja)
|
2013-04-17 |
2018-08-29 |
シグナル ファーマシューティカルズ,エルエルシー |
癌を治療するためのtorキナーゼ阻害剤及び5−置換キナゾリノン化合物を含む組合せ療法
|
NZ629230A
(en)
|
2013-04-17 |
2017-05-26 |
Signal Pharm Llc |
Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
|
AU2014254059B2
(en)
|
2013-04-17 |
2019-06-06 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a TOR kinase inhibitor and a cytidine analog for treating cancer
|
GB201309508D0
(en)
*
|
2013-05-28 |
2013-07-10 |
Redx Pharma Ltd |
Compounds
|
CN113831345A
(zh)
|
2013-05-29 |
2021-12-24 |
西格诺药品有限公司 |
二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
|
WO2015160882A1
(fr)
|
2014-04-16 |
2015-10-22 |
Signal Pharmaceuticals, Llc |
Formes solides comprenant de la 7-(6- (2-hydroxypropan-2-yl) pyridin-3-yl)-1-(trans)-4-méthoxycyclohexyl)-3, 4-dihydropyrazino[2,3-b] pyrazin-2(1h)-one, et un co-formeur, leurs compositions et leurs procédés d'utilisation
|
NZ714742A
(en)
|
2014-04-16 |
2017-04-28 |
Signal Pharm Llc |
Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
|
EP3131551A4
(fr)
|
2014-04-16 |
2017-09-20 |
Signal Pharmaceuticals, LLC |
Formes solides comprenant 1-éthyl-7-(2-méthyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl)-3,4-dihydropyrazino(2,3-b)pyrazin-2(1h)-one, et co-formateur, compositions et procédés d'utilisation de ces dernières
|
ES2823756T3
(es)
|
2014-04-16 |
2021-05-10 |
Signal Pharm Llc |
Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR
|
JP2017520603A
(ja)
|
2014-07-14 |
2017-07-27 |
シグナル ファーマシューティカルズ,エルエルシー |
置換ピロロピリミジン化合物を使用するがんの治療方法及びその組成物
|
NZ629796A
(en)
|
2014-07-14 |
2015-12-24 |
Signal Pharm Llc |
Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
|
BR112019027402A2
(pt)
|
2017-06-22 |
2020-07-07 |
Celgene Corporation |
tratamento de carcinoma hepatocelular caracterizado por infecção pelo vírus da hepatite b
|